Ebglyss
基本信息
-
商品名Ebglyss
-
产品编号EMEA/H/C/005894
-
通用名Lebrikizumab
-
活性成分Lebrikizumab
-
中文名称来金珠单抗
-
治疗领域Dermatitis, Atopic
-
ATC代码D11AH
-
上市许可持有人Almirall, S.A.
-
批准时间2023-11-16
-
版本
-
孤儿药no
-
仿制药no
-
生物类似药no
-
加速评审no
-
附加条件批准no
-
特殊评审no
-
额外监管yes
-
适应症Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.